Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Autolus announce a partnership or acquisition related to AUCATZYL® (obe-cel) by mid-2025?
Partnership with a pharmaceutical company • 33%
Acquisition by another company • 33%
No partnership or acquisition • 34%
Official announcements from Autolus Therapeutics
Autolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Best New Drug • 25%
Other • 25%
No major award • 25%
Innovation in Oncology • 25%